ACE Inhibitors versus Angiotensin Receptor Blockers for Cardiovascular Protection in Hypertension: A Meta-analysis of Major Cardiovascular Endpoints
Diabetes Asia Journal · 20.07.2026 · 3 (2) · 27-37
DOI: 10.62996/daj.82052026 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes Asia Journal, online erschienen am 20.07.2026. Verfasst von Anuradha V Dave und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) are both first-line agents for the pharmacological treatment of hypertension and are recommended Interchangeably by most major guidelines. Despite acting on the same renin-angiotensin-aldosterone system (RAAS) pathway, these two drug classes are not pharmacologically identical, and a body of trial and meta-analytic evidence has raised the question of whether they confer equivalent protection against hard cardiovascular endpoints —cardiovascular (CV) death, all-cause mortality, non-fatal stroke, and heart failure. This review summarizes the mechanistic rationale, synthesizes evidence from head-to-head and placebo-controlled trials, and situates the findings within current hypertension guidelines to provide a practical framework for clinical decision-making.
Zitieren
APA
Dave, A. V., Pandey, R., & Rastogi, M. (2026). ACE Inhibitors versus Angiotensin Receptor Blockers for Cardiovascular Protection in Hypertension: A Meta-analysis of Major Cardiovascular Endpoints. Diabetes Asia Journal, 3(2), 27-37. https://doi.org/10.62996/daj.82052026
Vancouver
Dave AV, Pandey R, Rastogi M. ACE Inhibitors versus Angiotensin Receptor Blockers for Cardiovascular Protection in Hypertension: A Meta-analysis of Major Cardiovascular Endpoints. Diabetes Asia Journal. 2026;3(2):27-37. doi:10.62996/daj.82052026
BibTeX
@article{Dave2026,
author = {Dave, Anuradha V and Pandey, Rashmi and Rastogi, Muskan},
title = {ACE Inhibitors versus Angiotensin Receptor Blockers for Cardiovascular Protection in Hypertension: A Meta-analysis of Major Cardiovascular Endpoints},
journal = {Diabetes Asia Journal},
year = {2026},
volume = {3},
number = {2},
pages = {27--37},
doi = {10.62996/daj.82052026}
}
EUVIMED